A library of 426 FDA-approved drugs was screened for in vitro activity against E. multilocularis metacestodes employing the phosphoglucose isomerase (PGI) assay. Initial screening at 20 µM revealed that 7 drugs induced considerable metacestode damage, and further dose-response studies revealed that bortezomib (BTZ), a proteasome inhibitor developed for the chemotherapy of myeloma, displayed hig...

A proteasome inhibitor, bortezomib (BTZ), was initially reported as an inhibitor of the NF-κB pathway, which plays a critical role in the pathogenesis of multiple myeloma (MM). The NF-κB activity of MM cells is mediated via two distinguishable pathways, canonical and non-canonical, which showed opposing action after BTZ treatment in MM cells. Recent studies of proteasome inhibition in MM cells ...

We study the dynamical behavior of the BTZ(Banados-Teitelboim-Zanelli) black hole with the low-energy string effective action. The perturbation analysis around the BTZ black hole reveals a mixing between the dilaton and other fields. Introducing the new gauge(dilaton gauge), we disentangle this mixing completely and obtain one decoupled dilaton equation. We obtain the decay rate Γ of BTZ black ...

BTZ black hole is interpreted as exact solution of 3d higher spin gauge theory. Solutions for free massless fields in BTZ black hole background are constructed with the help of the star-product algebra formalism underlying the formulation of 3d higher spin theory. It is shown that a part of higher spin symmetries remains unbroken for special values of the BTZ parameters.

Complexes of the form [Ru(diimine)2(btz)](2+) (btz = 1,1'-dibenzyl-4,4'-bi-1,2,3-triazolyl) are observed to undergo photochemical ejection of the btz ligand in the absence of any promotion through steric congestion to generate cis-bis(solvent) complexes [Ru(diimine)2(solvent)2](2+).

BACKGROUND The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptation to pharmacologically changed environments. Metabolic changes could therefore play an essential role in t...

Background: Although the introduction of protease inhibitor bortezomib (BTZ) and immunomodulatory agent lenalidomide has led to improved outcomes in patients with multiple myeloma (MM), the disease remains incurable. Gambogenic acid (GNA), a polyprenylated xanthone isolated from the traditional Chinese medicine gamboge, has been reported to have potent antitumor activity and can effectively inh...

We report the unprecedented observation and unequivocal crystallographic characterization of the metastable ligand loss intermediate solvento complex trans-[Ru(bpy)(k-btz)(k-btz)(NCMe)] (1a) that contains a monodentate chelate ligand. This and analogous complexes can be observed during the photolysis reactions of a family of complexes of the form [Ru(N _ N)(btz)2] 2+ (1a–d : btz=1,1’-dibenzyl-4...

The ubiqutin-proteasome system (UPS) plays a role in rituximab-chemotherapy resistance and bortezomib (BTZ) possesses caspase-dependent (i.e. Bak stabilization) and a less characterized caspase-independent mechanism-of-action(s). Here, we define BTZ-induced caspase-independent cell death pathways. A panel of rituximab-sensitive (RSCL), rituximab-resistant cell lines (RRCL) and primary tumor cel...